Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 8 of 8 for “"castrate-resistant prostate cancer"”.
-
Diethylstilbestrol Nanosuspensions for Prostate Cancer: Subcutaneous Sustained Release Formulations and Pre-clinical PK/PD Evaluations
Prostate cancer is the most common type of cancer and the second leading cause of cancer related deaths in men in the United States. According to the National Cancer Institute (NCI), 238,590 new cases with deaths of 29,720 from prostate cancer have been estimated for 2013. Diethylstilbestrol (DES) …
-
The Development of Gene Therapy by way of DNAzymes, and a Computational Tool that Predicts Efficient DNAzymes.
Prostate cancer (PCa) is the second highest cause of male cancer related death in the UK. The majority of aggressive cases of PCa spread outside of the organ to areas such as the bone where it becomes difficult to treat. Current treatment options focus on targeting androgens, the male sex hormones. …
-
Characterisation of Androgen Receptor Signalling and Metabolism in Prostate Cancer
Prostate cancer (PCa) is a prevalent disease which affects men worldwide. The Androgen Receptor (AR) is responsible for driving disease progression, therefore therapies often target this signalling axis. Eventually, these treatments fail and the cancer progresses to an aggressive, incurable stage …
-
The role of sphingosine kinases and dihydroceramide desaturase in regulating senescence in prostate cancer cells
… (S1P). SKs have been widely implicated in human cancers and inflammation. This has been demonstrated to be a consequence of the actions of S1P, which acts as a ligand at five G protein-coupled receptors - termed S1P1-5. S1P is also an intracellular effector which binds to proteins such as HDAC1/2 …
-
An innate immune response to DNA damage in prostate cancer
Each year in the UK 47,300 men are diagnosed with prostate cancer. Recent research has shown that up to 25% of men with mCRPC harbour mutations in DNA Repair genes BRCA1/ BRCA2 and ATM. This group has previously identified a molecular subtype in solid tumors characterised by STING mediated immune …
-
HDAC inhibition results in suppression of FOXM1 and genes associated with poor prognosis prostate cancer through p53 dependent and independent mechanisms
Prostate cancer is a disease of remarkable biological heterogeneity and is now the most commonly diagnosed malignancy in men worldwide. The standard of care combination of ADT and radiotherapy is highly effective in patients with locally advanced prostate cancer yet a third of patients relapse …
-
Integration of class 1 HDAC inhibitors into current treatments for prostate cancer
Introduction: <br/>Prostate Cancer (CaP) is the most common non-cutaneous malignancy in men in the Western world and therefore a significant health burden worldwide. First-line standard-of-care therapies for organ confined, locally advanced prostate cancer (LAPC) are surgery and radiotherapy. …
-
The Epigenetics of Small Cell Prostate Cancer
<p>Small cell prostate cancer (SCPC) is an androgen receptor (AR) negative variant that can develop during the progression of castration-resistant AR-positive (AR<sup>+</sup>) prostate adenocarcinomas. While rare at initial diagnosis, SCPC is present in 10-20% of patients resulting in an aggressive …